Identification

Name
Lithium
Accession Number
DB01356
Type
Small Molecule
Groups
Approved
Description

Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.

Structure
Thumb
Synonyms
  • Li(+)
  • Lithium cation
  • Lithium ion
  • Lithium, ion
  • Lithium, ion (li1+)
Product Ingredients
IngredientUNIICASInChI Key
Lithium carbonate2BMD2GNA4V554-13-2XGZVUEUWXADBQD-UHFFFAOYSA-L
Lithium citrate5Z6E9K79YV6080-58-6HXGWMCJZLNWEBC-UHFFFAOYSA-K
Lithium hydroxide monohydrateG51XLP968G1310-66-3GLXDVVHUTZTUQK-UHFFFAOYSA-M
Lithium succinateMD64P82Y2829126-50-9WAHQBNXSPALNEA-UHFFFAOYSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carbolith Cap 150mgCapsule150 mgOralValeant Canada Lp Valeant Canada S.E.C.1979-12-31Not applicableCanada
Carbolith Cap 300mgCapsule300 mgOralValeant Canada Lp Valeant Canada S.E.C.1971-12-31Not applicableCanada
Carbolith Capsules 600mgCapsule600 mgOralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Dom-lithium CarbonateCapsule600 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lithium CarbonateCapsule150 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lithium CarbonateCapsule300 mgOralDominion PharmacalNot applicableNot applicableCanada
Duralith Tab 300mgTablet, extended release300 mgOralJanssen Pharmaceuticals1985-12-312010-02-12Canada
Euro LithiumCapsule300 mgOralEuro Pharm International Canada Inc2008-02-262013-07-10Canada
Euro LithiumCapsule150 mgOralEuro Pharm International Canada Inc2008-02-262013-07-10Canada
LithaneCapsule150 mgOralErfa Canada 2012 Inc1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lithium CarbonateCapsule150 mgOralApotex Corporation2001-02-12Not applicableCanada
Apo-lithium CarbonateCapsule300 mgOralApotex Corporation2001-02-12Not applicableCanada
Lithium CarbonateCapsule300 mg/1OralContract Pharmacy Services Pa2017-09-19Not applicableUs
Lithium CarbonateCapsule600 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2009-02-03Not applicableUs
Lithium CarbonateCapsule300 mg/1OralMajor2003-02-24Not applicableUs
Lithium CarbonateCapsule150 mg/1OralRemedy Repack2013-05-082017-01-19Us
Lithium CarbonateCapsule300 mg/1OralPhysicians Total Care, Inc.1995-01-16Not applicableUs
Lithium CarbonateCapsule300 mg/1OralTYA Pharmaceuticals2009-12-15Not applicableUs31722 0545 10 nlmimage10 b83bdc5e
Lithium CarbonateCapsule600 mg/1OralWest Ward Pharmaceutical2002-05-01Not applicableUs
Lithium CarbonateCapsule300 mg/1OralProficient Rx LP2009-12-15Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lithium CarbonateTablet, extended release300 mg/1OralAlembic Pharmaceuticals Limited2017-02-21Not applicableUs
International/Other Brands
Eskalith / LithoTab
Categories
UNII
8H8Z5UER66
CAS number
7439-93-2
Weight
Average: 6.941
Monoisotopic: 7.016004049
Chemical Formula
Li
InChI Key
HBBGRARXTFLTSG-UHFFFAOYSA-N
InChI
InChI=1S/Li/q+1
IUPAC Name
lithium(1+) ion
SMILES
[Li+]

Pharmacology

Indication

Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.

Structured Indications
Pharmacodynamics

Although lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.

Mechanism of action

The precise mechanism of action of Li+ as a mood-stabilizing agent is currently unknown. It is possible that Li+ produces its effects by interacting with the transport of monovalent or divalent cations in neurons. An increasing number of scientists have come to the conclusion that the excitatory neurotransmitter glutamate is the key factor in understanding how lithium works. Lithium has been shown to change the inward and outward currents of glutamate receptors (especially GluR3), without a shift in reversal potential. Lithium has been found to exert a dual effect on glutamate receptors, acting to keep the amount of glutamate active between cells at a stable, healthy level, neither too much nor too little. It is postulated that too much glutamate in the space between neurons causes mania, and too little, depression. Another mechanism by which lithium might help to regulate mood include the non-competitive inhibition of an enzyme called inositol monophosphatase. Alternately lithium's action may be enhanced through the deactivation of the GSK-3B enzyme. The regulation of GSK-3B by lithium may affect the circadian clock. GSK-3 is known for phosphorylating and thus inactivating glycogen synthase. GSK-3B has also been implicated in the control of cellular response to damaged DNA. GSK-3 normally phosphorylates beta catenin, which leads to beta catenin degratation. When GSK-3 is inhibited, beta catenin increases and transgenic mice with overexpression of beta catenin express similar behaviour to mice treated with lithium. These results suggest that increase of beta catenin may be a possible pathway for the therapeutic action of lithium.

TargetActionsOrganism
UGlycogen synthase kinase-3 beta
inhibitor
Human
UInositol monophosphatase 1
inhibitor
Human
UInositol monophosphatase 2
inhibitor
Human
UGlutamate receptor 3
potentiator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineLithium may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineLithium may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineLithium may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lithium is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lithium.Experimental
AceclofenacThe serum concentration of Lithium can be increased when it is combined with Aceclofenac.Approved, Investigational
AcemetacinThe serum concentration of Lithium can be increased when it is combined with Acemetacin.Approved
AcepromazineLithium may increase the neurotoxic activities of Acepromazine.Approved, Vet Approved
AceprometazineLithium may increase the neurotoxic activities of Aceprometazine.Approved
AcetazolamideThe serum concentration of Lithium can be decreased when it is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineLithium may increase the neurotoxic activities of Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Lithium can be increased when it is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe serum concentration of Lithium can be increased when it is combined with Adapalene.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Lithium is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Lithium is combined with Agomelatine.Approved, Investigational
AlaproclateLithium may increase the serotonergic activities of Alaproclate.Experimental
AlclofenacThe serum concentration of Lithium can be increased when it is combined with Alclofenac.Approved, Withdrawn
AlcuroniumLithium may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Lithium is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lithium.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Lithium is combined with Allopregnanolone.Investigational
AlminoprofenThe serum concentration of Lithium can be increased when it is combined with Alminoprofen.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lithium.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lithium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Lithium is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lithium.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Lithium can be decreased when it is combined with Ambroxol acefyllinate.Experimental, Investigational
AmineptineLithium may increase the neurotoxic activities of Amineptine.Illicit, Withdrawn
AminophyllineThe serum concentration of Lithium can be decreased when it is combined with Aminophylline.Approved
AmiodaroneLithium may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideLithium may increase the neurotoxic activities of Amisulpride.Approved, Investigational
AmitriptylineLithium may increase the neurotoxic activities of Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lithium.Approved, Illicit
AmoxapineLithium may increase the neurotoxic activities of Amoxapine.Approved
AmperozideLithium may increase the neurotoxic activities of Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Lithium.Approved, Illicit
AnagrelideLithium may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideThe serum concentration of Lithium can be increased when it is combined with Andrographolide.Investigational
AnisodamineThe serum concentration of Lithium can be increased when it is combined with Anisodamine.Investigational
AntipyrineThe serum concentration of Lithium can be increased when it is combined with Antipyrine.Approved
ApocyninThe serum concentration of Lithium can be increased when it is combined with Apocynin.Investigational
ApremilastThe serum concentration of Lithium can be increased when it is combined with Apremilast.Approved, Investigational
AripiprazoleLithium may increase the neurotoxic activities of Aripiprazole.Approved, Investigational
Arsenic trioxideLithium may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherLithium may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Lithium is combined with Articaine.Approved
AsenapineLithium may increase the neurotoxic activities of Asenapine.Approved
AtracuriumLithium may increase the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateLithium may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneLithium may increase the neurotoxic activities of Azaperone.Investigational, Vet Approved
AzapropazoneThe serum concentration of Lithium can be increased when it is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Lithium can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.Approved
AzithromycinLithium may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Lithium is combined with Baclofen.Approved
BalsalazideThe serum concentration of Lithium can be increased when it is combined with Balsalazide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Lithium is combined with Barbital.Illicit
BedaquilineLithium may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Lithium can be increased when it is combined with Benazepril.Approved, Investigational
BendazacThe serum concentration of Lithium can be increased when it is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Lithium.Withdrawn
BenorilateThe serum concentration of Lithium can be increased when it is combined with Benorilate.Experimental
BenoxaprofenThe serum concentration of Lithium can be increased when it is combined with Benoxaprofen.Withdrawn
BenperidolLithium may increase the neurotoxic activities of Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lithium.Approved
BenzphetamineLithium may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BenzydamineThe serum concentration of Lithium can be increased when it is combined with Benzydamine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lithium is combined with Benzyl alcohol.Approved
BevoniumThe serum concentration of Lithium can be increased when it is combined with Bevonium.Experimental
BifeprunoxLithium may increase the neurotoxic activities of Bifeprunox.Investigational
BrexpiprazoleLithium may increase the neurotoxic activities of Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
BrinzolamideThe serum concentration of Lithium can be decreased when it is combined with Brinzolamide.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Lithium.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lithium.Approved, Illicit
BromfenacThe serum concentration of Lithium can be increased when it is combined with Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Lithium is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.Approved, Investigational
BromperidolLithium may increase the neurotoxic activities of Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lithium is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lithium is combined with Brotizolam.Approved, Investigational, Withdrawn
BucillamineThe serum concentration of Lithium can be increased when it is combined with Bucillamine.Investigational
BufexamacThe serum concentration of Lithium can be increased when it is combined with Bufexamac.Experimental
BumadizoneThe serum concentration of Lithium can be increased when it is combined with Bumadizone.Experimental
BumetanideThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lithium.Approved, Investigational
BuprenorphineLithium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lithium is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Lithium is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lithium is combined with Butamben.Approved
ButaperazineLithium may increase the neurotoxic activities of Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lithium.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lithium.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lithium.Approved
CaffeineThe serum concentration of Lithium can be decreased when it is combined with Caffeine.Approved
Calcitonin porcineThe serum concentration of Lithium can be decreased when it is combined with Calcitonin porcine.Experimental
CandesartanThe serum concentration of Lithium can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Lithium can be increased when it is combined with Candesartan cilexetil.Approved
CandoxatrilThe serum concentration of Lithium can be increased when it is combined with Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Lithium is combined with Canertinib.Investigational
CaptoprilThe serum concentration of Lithium can be increased when it is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.Approved, Investigational
Carbaspirin calciumThe serum concentration of Lithium can be increased when it is combined with Carbaspirin calcium.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lithium is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Lithium is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineLithium may increase the neurotoxic activities of Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Lithium is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Lithium.Withdrawn
CarprofenThe serum concentration of Lithium can be increased when it is combined with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe serum concentration of Lithium can be increased when it is combined with Castanospermine.Experimental
CelecoxibThe serum concentration of Lithium can be increased when it is combined with Celecoxib.Approved, Investigational
CeritinibLithium may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Lithium is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lithium is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lithium.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Lithium.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lithium.Approved
ChloroquineThe serum concentration of Lithium can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorphenamine.Approved
ChlorphentermineLithium may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineLithium may increase the neurotoxic activities of Chlorproethazine.Experimental
ChlorpromazineLithium may increase the neurotoxic activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneLithium may increase the neurotoxic activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorzoxazone.Approved
Choline magnesium trisalicylateThe serum concentration of Lithium can be increased when it is combined with Choline magnesium trisalicylate.Approved
CilazaprilThe serum concentration of Lithium can be increased when it is combined with Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lithium.Approved, Vet Approved
CiprofloxacinLithium may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideLithium may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisatracuriumLithium may increase the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateLithium may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CitalopramLithium may increase the serotonergic activities of Citalopram.Approved
ClarithromycinLithium may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Lithium is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lithium is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Lithium is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Lithium is combined with clomethiazole.Investigational
ClomipramineLithium may increase the neurotoxic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lithium is combined with Clonidine.Approved
ClonixinThe serum concentration of Lithium can be increased when it is combined with Clonixin.Approved
ClopenthixolLithium may increase the neurotoxic activities of Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.Approved, Illicit
ClothiapineLithium may increase the neurotoxic activities of Clothiapine.Experimental
ClozapineLithium may increase the neurotoxic activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lithium.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lithium.Approved, Illicit
CrizotinibLithium may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe serum concentration of Lithium can be increased when it is combined with Curcumin.Investigational
CyamemazineLithium may increase the neurotoxic activities of Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lithium is combined with Cyclizine.Approved
CyclobenzaprineLithium may increase the neurotoxic activities of Cyclobenzaprine.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Lithium is combined with Cyproheptadine.Approved
D-LimoneneThe serum concentration of Lithium can be increased when it is combined with D-Limonene.Investigational
DantroleneThe risk or severity of adverse effects can be increased when Lithium is combined with Dantrolene.Approved
DapiprazoleLithium may increase the neurotoxic activities of Dapiprazole.Approved
DapoxetineLithium may increase the serotonergic activities of Dapoxetine.Investigational
DecamethoniumLithium may increase the neuromuscular blocking activities of Decamethonium.Approved
DelaprilThe serum concentration of Lithium can be increased when it is combined with Delapril.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Lithium is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lithium.Approved
DesipramineLithium may increase the neurotoxic activities of Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Lithium is combined with Desloratadine.Approved, Investigational
DesmopressinThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.Approved
DesvenlafaxineLithium may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Lithium is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lithium is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium.Approved, Vet Approved
DextroamphetamineLithium may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lithium.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lithium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lithium.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lithium.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lithium.Approved, Illicit, Vet Approved
DibenzepinLithium may increase the neurotoxic activities of Dibenzepin.Experimental
DiclofenacThe serum concentration of Lithium can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe serum concentration of Lithium can be decreased when it is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Lithium is combined with Diethyl ether.Experimental
DiethylpropionLithium may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Lithium is combined with Difenoxin.Approved, Illicit
DifenpiramideThe serum concentration of Lithium can be increased when it is combined with Difenpiramide.Experimental
DiflunisalThe serum concentration of Lithium can be increased when it is combined with Diflunisal.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lithium.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydromorphine.Experimental, Illicit
DiltiazemDiltiazem may increase the neurotoxic activities of Lithium.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Lithium is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lithium.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lithium.Approved, Illicit
DisopyramideLithium may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineLithium may increase the neurotoxic activities of Dixyrazine.Experimental
DofetilideLithium may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronLithium may increase the QTc-prolonging activities of Dolasetron.Approved
Domoic AcidLithium may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DomperidoneLithium may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Lithium is combined with Doramectin.Vet Approved
DorzolamideThe serum concentration of Lithium can be decreased when it is combined with Dorzolamide.Approved
DosulepinLithium may increase the neurotoxic activities of Dosulepin.Approved
Doxacurium chlorideLithium may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxepinLithium may increase the neurotoxic activities of Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lithium is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Illicit
DronedaroneLithium may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lithium is combined with Drotebanol.Experimental, Illicit
DroxicamThe serum concentration of Lithium can be increased when it is combined with Droxicam.Approved
DuloxetineLithium may increase the serotonergic activities of Duloxetine.Approved
DuvelisibThe serum concentration of Lithium can be increased when it is combined with Duvelisib.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.Approved
DyphyllineThe serum concentration of Lithium can be decreased when it is combined with Dyphylline.Approved
E-6201The serum concentration of Lithium can be increased when it is combined with E-6201.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Lithium is combined with Ecgonine.Experimental, Illicit
EcopipamLithium may increase the neurotoxic activities of Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Lithium is combined with Efavirenz.Approved, Investigational
ElcatoninThe serum concentration of Lithium can be decreased when it is combined with Elcatonin.Experimental
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lithium.Approved, Investigational
EliglustatLithium may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Lithium is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Lithium can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Lithium can be increased when it is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lithium.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Lithium is combined with Entacapone.Approved, Investigational
EpirizoleThe serum concentration of Lithium can be increased when it is combined with Epirizole.Approved
EplerenoneThe serum concentration of Lithium can be increased when it is combined with Eplerenone.Approved
EprosartanThe serum concentration of Lithium can be increased when it is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lithium.Approved
ErythromycinLithium may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramLithium may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineLithium may increase the neurotoxic activities of Esmirtazapine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lithium.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lithium.Approved
Etacrynic acidThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.Approved
EtanerceptThe serum concentration of Lithium can be increased when it is combined with Etanercept.Approved, Investigational
EthanolLithium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.Approved, Illicit, Withdrawn
EthenzamideThe serum concentration of Lithium can be increased when it is combined with Ethenzamide.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Lithium is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lithium is combined with Ethotoin.Approved
EthoxzolamideThe serum concentration of Lithium can be decreased when it is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lithium is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lithium is combined with Etizolam.Approved
EtodolacThe serum concentration of Lithium can be increased when it is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe serum concentration of Lithium can be increased when it is combined with Etofenamate.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.Approved
EtoperidoneLithium may increase the serotonergic activities of Etoperidone.Withdrawn
EtoricoxibThe serum concentration of Lithium can be increased when it is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Etorphine.Illicit, Vet Approved
Evening primrose oilThe serum concentration of Lithium can be increased when it is combined with Evening primrose oil.Approved, Investigational
exisulindThe serum concentration of Lithium can be increased when it is combined with exisulind.Investigational
EzogabineThe risk or severity of adverse effects can be increased when Lithium is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lithium is combined with Felbamate.Approved
FelbinacThe serum concentration of Lithium can be increased when it is combined with Felbinac.Experimental
FenbufenThe serum concentration of Lithium can be increased when it is combined with Fenbufen.Approved
FencamfamineLithium may increase the neurotoxic activities of Fencamfamine.Approved, Illicit, Withdrawn
FenoprofenThe serum concentration of Lithium can be increased when it is combined with Fenoprofen.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.Approved, Illicit, Investigational, Vet Approved
FentiazacThe serum concentration of Lithium can be increased when it is combined with Fentiazac.Experimental
FeprazoneThe serum concentration of Lithium can be increased when it is combined with Feprazone.Experimental
Ferulic acidThe serum concentration of Lithium can be increased when it is combined with Ferulic acid.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Lithium is combined with Fexofenadine.Approved
FimasartanThe serum concentration of Lithium can be increased when it is combined with Fimasartan.Approved, Investigational
FlecainideLithium may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Lithium is combined with Flibanserin.Approved
FloctafenineThe serum concentration of Lithium can be increased when it is combined with Floctafenine.Approved, Withdrawn
FluanisoneLithium may increase the neurotoxic activities of Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lithium is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Flunitrazepam.Approved, Illicit
FlunixinThe serum concentration of Lithium can be increased when it is combined with Flunixin.Vet Approved
FlunoxaprofenThe serum concentration of Lithium can be increased when it is combined with Flunoxaprofen.Experimental
FluoxetineLithium may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolLithium may increase the neurotoxic activities of Flupentixol.Approved, Withdrawn
FluphenazineLithium may increase the neurotoxic activities of Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium.Approved, Illicit
FlurbiprofenThe serum concentration of Lithium can be increased when it is combined with Flurbiprofen.Approved, Investigational
FluspirileneLithium may increase the neurotoxic activities of Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lithium is combined with Fluticasone propionate.Approved
FluvoxamineLithium may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
ForasartanThe serum concentration of Lithium can be increased when it is combined with Forasartan.Experimental
FosinoprilThe serum concentration of Lithium can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lithium.Approved
FospropofolThe risk or severity of adverse effects can be increased when Lithium is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lithium.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.Approved, Investigational, Vet Approved
FurosemideThe serum concentration of Lithium can be decreased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Lithium is combined with Gabapentin Enacarbil.Approved
Gadobenic acidLithium may increase the QTc-prolonging activities of Gadobenic acid.Approved
GallamineLithium may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideLithium may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lithium.Approved, Illicit, Investigational
GemifloxacinLithium may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineLithium may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Lithium is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Lithium is combined with Glutethimide.Approved, Illicit
GoserelinLithium may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronLithium may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuacetisalThe serum concentration of Lithium can be increased when it is combined with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Lithium is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lithium.Approved, Illicit, Withdrawn
HaloperidolLithium may increase the neurotoxic activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lithium.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Lithium.Experimental
HeroinThe risk or severity of adverse effects can be increased when Lithium is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lithium.Approved
HigenamineThe serum concentration of Lithium can be increased when it is combined with Higenamine.Investigational
Human calcitoninThe serum concentration of Lithium can be decreased when it is combined with Human calcitonin.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Lithium.Experimental
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Vet Approved
HydrocodoneLithium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.Approved, Illicit
HydroxyamphetamineLithium may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
IbuprofenThe serum concentration of Lithium can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe serum concentration of Lithium can be increased when it is combined with Ibuproxam.Withdrawn
IbutilideLithium may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe serum concentration of Lithium can be increased when it is combined with Icatibant.Approved
IloperidoneLithium may increase the neurotoxic activities of Iloperidone.Approved
ImidaprilThe serum concentration of Lithium can be increased when it is combined with Imidapril.Investigational
Imidazole salicylateThe serum concentration of Lithium can be increased when it is combined with Imidazole salicylate.Experimental
ImipramineLithium may increase the neurotoxic activities of Imipramine.Approved
IndalpineLithium may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
IndiplonThe risk or severity of adverse effects can be increased when Lithium is combined with Indiplon.Investigational
IndobufenThe serum concentration of Lithium can be increased when it is combined with Indobufen.Investigational
IndomethacinThe serum concentration of Lithium can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe serum concentration of Lithium can be increased when it is combined with Indoprofen.Withdrawn
Iofetamine I-123Lithium may decrease the stimulatory activities of Iofetamine I-123.Approved
IprindoleLithium may increase the neurotoxic activities of Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Lithium.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.Withdrawn
IrbesartanThe serum concentration of Lithium can be increased when it is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lithium.Approved, Vet Approved
IsoxicamThe serum concentration of Lithium can be increased when it is combined with Isoxicam.Withdrawn
KebuzoneThe serum concentration of Lithium can be increased when it is combined with Kebuzone.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Lithium is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Ketobemidone.Approved, Investigational
KetoprofenThe serum concentration of Lithium can be increased when it is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe serum concentration of Lithium can be increased when it is combined with Ketorolac.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lithium is combined with Lamotrigine.Approved, Investigational
LeflunomideThe serum concentration of Lithium can be increased when it is combined with Leflunomide.Approved, Investigational
LenvatinibLithium may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLithium may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lithium is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lithium.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Lithium is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lithium is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lithium is combined with Levodopa.Approved
LevofloxacinLithium may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lithium.Approved, Investigational
LevomilnacipranLithium may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lithium.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lithium.Approved, Investigational
LisdexamfetamineLithium may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Lithium can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe serum concentration of Lithium can be increased when it is combined with Lisofylline.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lithium is combined with Lofentanil.Illicit
LofepramineLithium may increase the neurotoxic activities of Lofepramine.Experimental
LonazolacThe serum concentration of Lithium can be increased when it is combined with Lonazolac.Experimental
LopinavirLithium may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Lithium is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Lithium is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lithium.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lithium is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Lormetazepam.Approved
LornoxicamThe serum concentration of Lithium can be increased when it is combined with Lornoxicam.Approved, Investigational
LosartanThe serum concentration of Lithium can be increased when it is combined with Losartan.Approved
LoxapineLithium may increase the neurotoxic activities of Loxapine.Approved
LoxoprofenThe serum concentration of Lithium can be increased when it is combined with Loxoprofen.Approved, Investigational
LumefantrineLithium may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe serum concentration of Lithium can be increased when it is combined with Lumiracoxib.Approved, Investigational
LurasidoneLithium may increase the neurotoxic activities of Lurasidone.Approved
Magnesium salicylateThe serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.Approved
MasoprocolThe serum concentration of Lithium can be increased when it is combined with Masoprocol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Lithium.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Lithium is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Lithium is combined with Meclizine.Approved
Meclofenamic acidThe serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Lithium is combined with Medetomidine.Vet Approved
Mefenamic acidThe serum concentration of Lithium can be increased when it is combined with Mefenamic acid.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lithium.Approved, Nutraceutical, Vet Approved
MeloxicamThe serum concentration of Lithium can be increased when it is combined with Meloxicam.Approved, Vet Approved
MelperoneLithium may increase the neurotoxic activities of Melperone.Approved, Investigational
MephedroneLithium may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineLithium may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Lithium is combined with Meptazinol.Experimental
MequitazineLithium may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe serum concentration of Lithium can be increased when it is combined with Mesalazine.Approved
MesoridazineLithium may increase the neurotoxic activities of Mesoridazine.Approved, Investigational
MetamizoleThe serum concentration of Lithium can be increased when it is combined with Metamizole.Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Lithium is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lithium.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lithium is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineLithium may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Lithium is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lithium is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe serum concentration of Lithium can be decreased when it is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Lithium is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lithium.Approved
MethotrimeprazineLithium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lithium.Approved, Investigational, Vet Approved
MethoxyphenamineLithium may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Lithium is combined with Methsuximide.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Lithium is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Lithium.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lithium.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Lithium is combined with Metoclopramide.Approved, Investigational
MetocurineLithium may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideLithium may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneMetolazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
MetyrosineLithium may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.Approved, Illicit
MidomafetamineLithium may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Lithium.Approved, Investigational
MilnacipranLithium may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Lithium.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Investigational
MirtazapineLithium may increase the neurotoxic activities of Mirtazapine.Approved
MivacuriumLithium may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe serum concentration of Lithium can be increased when it is combined with Mizoribine.Investigational
MMDALithium may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lithium.Approved
MoexiprilThe serum concentration of Lithium can be increased when it is combined with Moexipril.Approved
MofebutazoneThe serum concentration of Lithium can be increased when it is combined with Mofebutazone.Experimental
MolindoneLithium may increase the neurotoxic activities of Molindone.Approved
MoperoneLithium may increase the neurotoxic activities of Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lithium.Approved, Investigational
MosapramineLithium may increase the neurotoxic activities of Mosapramine.Experimental
MoxifloxacinLithium may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Investigational
NabumetoneThe serum concentration of Lithium can be increased when it is combined with Nabumetone.Approved
NafamostatThe serum concentration of Lithium can be increased when it is combined with Nafamostat.Approved, Investigational
NaftifineThe serum concentration of Lithium can be increased when it is combined with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lithium.Approved
NaproxenThe serum concentration of Lithium can be increased when it is combined with Naproxen.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lithium.Approved, Investigational
NefazodoneLithium may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NeosaxitoxinLithium may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe serum concentration of Lithium can be increased when it is combined with Nepafenac.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Lithium.Withdrawn
NifenazoneThe serum concentration of Lithium can be increased when it is combined with Nifenazone.Experimental
Niflumic AcidThe serum concentration of Lithium can be increased when it is combined with Niflumic Acid.Approved
NilotinibLithium may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe serum concentration of Lithium can be increased when it is combined with Nimesulide.Approved, Investigational, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lithium.Approved
NitroaspirinThe serum concentration of Lithium can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lithium.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Lithium is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Lithium is combined with Normethadone.Approved, Illicit
NortriptylineLithium may increase the neurotoxic activities of Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Lithium.Withdrawn
OfloxacinLithium may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineLithium may increase the neurotoxic activities of Olanzapine.Approved, Investigational
OlmesartanThe serum concentration of Lithium can be increased when it is combined with Olmesartan.Approved, Investigational
OlopatadineThe serum concentration of Lithium can be increased when it is combined with Olopatadine.Approved
OlsalazineThe serum concentration of Lithium can be increased when it is combined with Olsalazine.Approved
OmapatrilatThe serum concentration of Lithium can be increased when it is combined with Omapatrilat.Investigational
OndansetronLithium may increase the neurotoxic activities of Ondansetron.Approved
OpipramolLithium may increase the neurotoxic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Lithium is combined with Opium.Approved, Illicit
OrgoteinThe serum concentration of Lithium can be increased when it is combined with Orgotein.Vet Approved
OrphenadrineLithium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantLithium may increase the neurotoxic activities of Osanetant.Investigational
OxaprozinThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lithium.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Lithium is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Lithium is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lithium.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lithium.Approved, Investigational, Vet Approved
OxypertineLithium may increase the neurotoxic activities of Oxypertine.Experimental
OxyphenbutazoneThe serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.Approved, Withdrawn
PaliperidoneLithium may increase the neurotoxic activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Lithium.Approved, Investigational
PancuroniumLithium may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatLithium may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeLithium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParecoxibThe serum concentration of Lithium can be increased when it is combined with Parecoxib.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.Approved
ParoxetineLithium may increase the serotonergic activities of Paroxetine.Approved, Investigational
ParthenolideThe serum concentration of Lithium can be increased when it is combined with Parthenolide.Investigational
PazopanibLithium may increase the QTc-prolonging activities of Pazopanib.Approved
PenfluridolLithium may increase the neurotoxic activities of Penfluridol.Experimental
PentamidineLithium may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lithium.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
PerazineLithium may increase the neurotoxic activities of Perazine.Investigational
PerflutrenLithium may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe serum concentration of Lithium can be increased when it is combined with Perindopril.Approved
PerospironeLithium may increase the neurotoxic activities of Perospirone.Approved
PerphenazineLithium may increase the neurotoxic activities of Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lithium.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Lithium is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.Approved
PhenibutThe risk or severity of adverse effects can be increased when Lithium is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Lithium.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Lithium is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lithium is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Lithium.Withdrawn
PhentermineLithium may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenylbutazoneThe serum concentration of Lithium can be increased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lithium.Approved, Vet Approved
PimecrolimusThe serum concentration of Lithium can be increased when it is combined with Pimecrolimus.Approved, Investigational
PimozideLithium may increase the neurotoxic activities of Pimozide.Approved
PipamperoneLithium may increase the neurotoxic activities of Pipamperone.Approved, Investigational
PipecuroniumLithium may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineLithium may increase the neurotoxic activities of Pipotiazine.Approved, Investigational
PiretanideThe serum concentration of Lithium can be decreased when it is combined with Piretanide.Experimental
PirfenidoneThe serum concentration of Lithium can be increased when it is combined with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lithium is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Lithium.Approved
PiroxicamThe serum concentration of Lithium can be increased when it is combined with Piroxicam.Approved, Investigational
PirprofenThe serum concentration of Lithium can be increased when it is combined with Pirprofen.Experimental
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Lithium.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Lithium is combined with Pizotifen.Approved
PolythiazidePolythiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lithium is combined with Pomalidomide.Approved
Potassium IodidePotassium Iodide may increase the hypothyroid activities of Lithium.Approved
PramipexoleLithium may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Pramocaine.Approved
PranoprofenThe serum concentration of Lithium can be increased when it is combined with Pranoprofen.Experimental, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lithium.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lithium.Approved
PrimaquineLithium may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Primidone.Approved, Vet Approved
ProcainamideLithium may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lithium.Approved, Investigational, Vet Approved
ProchlorperazineLithium may increase the neurotoxic activities of Prochlorperazine.Approved, Vet Approved
ProglumetacinThe serum concentration of Lithium can be increased when it is combined with Proglumetacin.Experimental
PromazineLithium may increase the neurotoxic activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Lithium.Approved
PropacetamolThe serum concentration of Lithium can be increased when it is combined with Propacetamol.Approved, Investigational
PropafenoneLithium may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Lithium is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lithium.Approved, Vet Approved
PropericiazineLithium may increase the neurotoxic activities of Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lithium.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lithium is combined with Propoxycaine.Approved
PropyphenazoneThe serum concentration of Lithium can be increased when it is combined with Propyphenazone.Experimental
ProquazoneThe serum concentration of Lithium can be increased when it is combined with Proquazone.Experimental
ProthipendylLithium may increase the neurotoxic activities of Prothipendyl.Investigational
ProtriptylineLithium may increase the neurotoxic activities of Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Lithium is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Lithium is combined with PSD502.Investigational
PseudoephedrineLithium may decrease the stimulatory activities of Pseudoephedrine.Approved
PTC299The serum concentration of Lithium can be increased when it is combined with PTC299.Investigational
PyrantelLithium may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lithium.Approved, Illicit
QuetiapineLithium may increase the neurotoxic activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Lithium.Approved
QuinaprilThe serum concentration of Lithium can be increased when it is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
QuinidineLithium may increase the QTc-prolonging activities of Quinidine.Approved
QuinineLithium may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Quinisocaine.Experimental
RacloprideLithium may increase the neurotoxic activities of Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Lithium is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Lithium can be increased when it is combined with Ramipril.Approved
RapacuroniumLithium may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.Approved
RemoxiprideLithium may increase the neurotoxic activities of Remoxipride.Approved, Withdrawn
RescinnamineThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.Approved
ReserpineLithium may increase the neurotoxic activities of Reserpine.Approved, Investigational
ResveratrolThe serum concentration of Lithium can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RisperidoneLithium may increase the neurotoxic activities of Risperidone.Approved, Investigational
RitanserinLithium may increase the neurotoxic activities of Ritanserin.Investigational
RitobegronLithium may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lithium.Approved
RocuroniumLithium may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe serum concentration of Lithium can be increased when it is combined with Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Lithium is combined with Romifidine.Vet Approved
RopiniroleLithium may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium.Approved
RotigotineLithium may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lithium.Approved
SacubitrilThe serum concentration of Lithium can be increased when it is combined with Sacubitril.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Lithium.Withdrawn
SalicylamideThe serum concentration of Lithium can be increased when it is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Lithium can be increased when it is combined with Salicylic acid.Approved, Vet Approved
Salmon CalcitoninThe serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin.Approved, Investigational
SalsalateThe serum concentration of Lithium can be increased when it is combined with Salsalate.Approved
SaprisartanThe serum concentration of Lithium can be increased when it is combined with Saprisartan.Experimental
SaquinavirLithium may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaralasinThe serum concentration of Lithium can be increased when it is combined with Saralasin.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Lithium is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lithium.Approved, Investigational, Vet Approved
SemapimodThe serum concentration of Lithium can be increased when it is combined with Semapimod.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Lithium is combined with Sepranolone.Investigational
SeratrodastThe serum concentration of Lithium can be increased when it is combined with Seratrodast.Approved
SerrapeptaseThe serum concentration of Lithium can be increased when it is combined with Serrapeptase.Investigational
SertindoleLithium may increase the neurotoxic activities of Sertindole.Approved, Investigational, Withdrawn
SertralineLithium may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.Approved, Vet Approved
Sodium bicarbonateSodium bicarbonate may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.Approved
Sodium ChlorideSodium Chloride may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
SotalolLithium may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Lithium can be increased when it is combined with Spirapril.Approved
SRT501The serum concentration of Lithium can be increased when it is combined with SRT501.Investigational
StiripentolThe risk or severity of adverse effects can be increased when Lithium is combined with Stiripentol.Approved
SuccinylcholineLithium may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.Approved, Investigational
SulfasalazineThe serum concentration of Lithium can be increased when it is combined with Sulfasalazine.Approved
SulfisoxazoleLithium may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe serum concentration of Lithium can be increased when it is combined with Sulindac.Approved
SulpirideLithium may increase the neurotoxic activities of Sulpiride.Approved, Investigational
SultoprideLithium may increase the neurotoxic activities of Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lithium.Approved, Investigational
SuprofenThe serum concentration of Lithium can be increased when it is combined with Suprofen.Approved, Withdrawn
SuvorexantLithium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
SuxibuzoneThe serum concentration of Lithium can be increased when it is combined with Suxibuzone.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Lithium is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
TarenflurbilThe serum concentration of Lithium can be increased when it is combined with Tarenflurbil.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Lithium is combined with Tasimelteon.Approved
TasosartanThe serum concentration of Lithium can be increased when it is combined with Tasosartan.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Lithium.Approved
TelavancinLithium may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinLithium may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe serum concentration of Lithium can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lithium.Approved
TemocaprilThe serum concentration of Lithium can be increased when it is combined with Temocapril.Experimental, Investigational
TenidapThe serum concentration of Lithium can be increased when it is combined with Tenidap.Experimental
TenoxicamThe serum concentration of Lithium can be increased when it is combined with Tenoxicam.Approved
TepoxalinThe serum concentration of Lithium can be increased when it is combined with Tepoxalin.Vet Approved
TeriflunomideThe serum concentration of Lithium can be increased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium.Approved
TetracaineThe risk or severity of adverse effects can be increased when Lithium is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineLithium may increase the neurotoxic activities of Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Lithium is combined with Tetrodotoxin.Investigational
ThalidomideLithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Lithium can be decreased when it is combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.Approved, Vet Approved
ThiopropazateLithium may increase the neurotoxic activities of Thiopropazate.Experimental
ThioproperazineLithium may increase the neurotoxic activities of Thioproperazine.Approved
ThioridazineLithium may increase the neurotoxic activities of Thioridazine.Approved, Withdrawn
ThiothixeneLithium may increase the neurotoxic activities of Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lithium is combined with Tiagabine.Approved
TianeptineLithium may increase the neurotoxic activities of Tianeptine.Approved, Investigational
TiaprideLithium may increase the neurotoxic activities of Tiapride.Approved, Investigational
Tiaprofenic acidThe serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.Approved
TiletamineThe risk or severity of adverse effects can be increased when Lithium is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Lithium is combined with Tilidine.Experimental
TinoridineThe serum concentration of Lithium can be increased when it is combined with Tinoridine.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Lithium is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lithium is combined with Tolcapone.Approved, Withdrawn
TolevamerThe serum concentration of Lithium can be decreased when it is combined with Tolevamer.Approved
Tolfenamic AcidThe serum concentration of Lithium can be increased when it is combined with Tolfenamic Acid.Approved
TolmetinThe serum concentration of Lithium can be increased when it is combined with Tolmetin.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Lithium.Approved
TopiramateThe serum concentration of Lithium can be increased when it is combined with Topiramate.Approved
TorasemideThe serum concentration of Lithium can be decreased when it is combined with Torasemide.Approved
ToremifeneLithium may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.Approved, Investigational
TrandolaprilThe serum concentration of Lithium can be increased when it is combined with Trandolapril.Approved
TranilastThe serum concentration of Lithium can be increased when it is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lithium.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Lithium.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lithium.Approved
TribenosideThe serum concentration of Lithium can be increased when it is combined with Tribenoside.Experimental
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Lithium is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Lithium is combined with Trichloroethylene.Experimental
TrifluoperazineLithium may increase the neurotoxic activities of Trifluoperazine.Approved
TrifluperidolLithium may increase the neurotoxic activities of Trifluperidol.Experimental
TriflupromazineLithium may increase the neurotoxic activities of Triflupromazine.Approved, Vet Approved
TrimipramineLithium may increase the neurotoxic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Lithium is combined with Triprolidine.Approved
TriptolideThe serum concentration of Lithium can be increased when it is combined with Triptolide.Investigational
TropisetronTropisetron may increase the serotonergic activities of Lithium.Approved, Investigational
TubocurarineLithium may increase the neuromuscular blocking activities of Tubocurarine.Approved
ValdecoxibThe serum concentration of Lithium can be increased when it is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lithium.Approved, Investigational
ValsartanThe serum concentration of Lithium can be increased when it is combined with Valsartan.Approved, Investigational
VandetanibLithium may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumLithium may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibLithium may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineLithium may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideLithium may increase the neurotoxic activities of Veralipride.Experimental
VerapamilVerapamil may increase the neurotoxic activities of Lithium.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lithium is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Lithium.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Lithium is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lithium.Approved
XenonThe risk or severity of adverse effects can be increased when Lithium is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Lithium is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium.Approved, Illicit, Investigational
ZaltoprofenThe serum concentration of Lithium can be increased when it is combined with Zaltoprofen.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lithium is combined with Ziconotide.Approved
ZileutonThe serum concentration of Lithium can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineLithium may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneLithium may increase the neurotoxic activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Lithium can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lithium.Approved, Investigational
ZolpidemLithium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe serum concentration of Lithium can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Lithium is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lithium.Approved
ZotepineLithium may increase the neurotoxic activities of Zotepine.Approved, Investigational
ZuclopenthixolLithium may increase the neurotoxic activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid iodine supplements.
  • Do not change your salt intake from day to day without telling your doctor.
  • Take with food to reduce irritation. Drink plenty of liquids.

References

Synthesis Reference

Jean-Paul Gabano, "Electrolyte for a lithium/thionyl chloride electric cell, a method of preparing said electrolyte and an electric cell which includes said electrolyte." U.S. Patent US4375502, issued 0000.

US4375502
General References
  1. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK: Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62(1):50-60. doi: 10.1159/000314310. Epub 2010 May 7. [PubMed:20453535]
  2. ILO: Lithium [Link]
External Links
Human Metabolome Database
HMDB05949
KEGG Compound
C15473
PubChem Compound
28486
PubChem Substance
46505392
ChemSpider
26502
ChEBI
49713
ChEMBL
CHEMBL1234004
Therapeutic Targets Database
DNC000879
PharmGKB
PA450243
HET
LI
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lithium
ATC Codes
D11AX04 — Lithium succinateN05AN01 — Lithium
AHFS Codes
  • 28:28.00 — Antimanic Agents
PDB Entries
1dgd / 1e5k / 1h4c / 1h4d / 1h4e / 1hjj / 1hjl / 1knw / 1mgw / 1nqj
show 59 more
FDA label
Download (200 KB)
MSDS
Download (72.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentBipolar Disorder (BD)1
1CompletedTreatmentDepression / Major Depressive Disorder (MDD)1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentSpinal Cord Injuries (SCI)1
1CompletedTreatmentSpinocerebellar Ataxia Type I1
1RecruitingBasic ScienceDrug Mechanism1
1TerminatedSupportive CareBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Neurotoxicity / Tumors, Solid1
1WithdrawnNot AvailableGeneralized Anxiety Disease1
1WithdrawnBasic ScienceCombat Posttraumatic Stess Disorder / Mild Traumatic Brain Injury (MTBI)1
1, 2CompletedSupportive CareSmall Cell Lung Carcinoma1
1, 2CompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine1
1, 2CompletedTreatmentCorticobasal Degeneration / Progressive Supranuclear Palsy (PSP)1
1, 2CompletedTreatmentDisseminated Sclerosis1
1, 2CompletedTreatmentSpinal Cord Injuries (SCI)3
1, 2RecruitingTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD)1
1, 2RecruitingTreatmentNiemann-Pick Disease, Type C11
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentBipolar I Disorder Without Psychotic Symptoms1
2CompletedTreatmentBorderline Personality Disorder (BPD) / Depression Not Otherwise Specified / Dysthymic Disorder / Major Depressive Disorder (MDD)1
2CompletedTreatmentCannabis Dependence / Substance Withdrawal Syndrome1
2CompletedTreatmentDepression1
2CompletedTreatmentDifferentiated Thyroid Carcinoma / Thyroid Cancers1
2CompletedTreatmentHuntington's Disease (HD)1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentNeurocostal neuralgia / Pain, Neuropathic / Spinal Cord Injuries (SCI)1
2CompletedTreatmentSPINOCEREBELLAR ATAXIA 21
2CompletedTreatmentSpinal Cord Injuries (SCI)1
2Enrolling by InvitationBasic ScienceTreatment Resistant Depression (TRD)1
2RecruitingTreatmentAcute Agitation / Alzheimer's Disease (AD) / Psychosis1
2RecruitingTreatmentFracture Bone1
2RecruitingTreatmentFrontotemporal Dementia (FTD)1
2TerminatedTreatmentBrain Cancer1
2TerminatedTreatmentMedullary Thyroid Cancer (MTC)1
2TerminatedTreatmentMultiple System Atrophy (MSA)1
2Unknown StatusPreventionAlzheimer's Disease (AD) / Cognitive Impairments1
2Unknown StatusTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2WithdrawnTreatmentDepression, Bipolar1
2, 3CompletedTreatmentBipolar Disorder (BD)1
2, 3CompletedTreatmentDepression / Suicide, Attempted1
2, 3CompletedTreatmentMachado Joseph Disease / Spinocerebellar Ataxia Type 31
2, 3RecruitingPreventionBipolar Disorder (BD) / Depressive Disorders / Suicide / Suicide, Attempted1
2, 3TerminatedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
3CompletedDiagnosticBipolar Disorder (BD)1
3CompletedPreventionBipolar Disorder (BD)1
3CompletedPreventionBipolar I Disorder1
3CompletedTreatmentAcute Bipolar Depression1
3CompletedTreatmentAggressive Behavior / Oppositional Defiant Disorder1
3CompletedTreatmentAlcohol Dependence / Bipolar I Disorder1
3CompletedTreatmentBipolar Disorder (BD)5
3CompletedTreatmentBipolar Disorder (BD) / Depression1
3CompletedTreatmentBipolar Disorder (BD) / Mania1
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar Disorder Mania1
3CompletedTreatmentBipolar I Disorder1
3CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
3CompletedTreatmentMania1
3CompletedTreatmentManic or Mixed Episode Associated With Bipolar I Disorder1
3CompletedTreatmentStrokes1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD)1
3TerminatedTreatmentMajor Depressive Disorder (MDD)1
3Unknown StatusTreatmentBipolar Disorder (BD) / Mania1
4Active Not RecruitingBasic ScienceBipolar I Disorder1
4Active Not RecruitingTreatmentBipolar Disorder (BD)1
4CompletedNot AvailableBipolar Disorder (BD)1
4CompletedBasic ScienceBipolar Disorder (BD)1
4CompletedDiagnosticBipolar Disorder (BD)1
4CompletedPreventionDepression, Bipolar1
4CompletedTreatmentAcute Mania1
4CompletedTreatmentAcute Mania in Bipolar Disorder1
4CompletedTreatmentBipolar Disorder (BD)7
4CompletedTreatmentBipolar Disorder (BD) / Depression2
4CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar1
4CompletedTreatmentBipolar Disorder (BD) / Depression / Depressive Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Mania2
4CompletedTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS / Schizophrenic Disorders1
4CompletedTreatmentBipolar I Disorder / Bipolar II Disorder1
4CompletedTreatmentBipolar Type II Disorder1
4CompletedTreatmentDepression4
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Neurocognitive Disturbance1
4CompletedTreatmentMajor Depressive Disorder (MDD)2
4CompletedTreatmentMajor Depressive Disorder (MDD) / Suicidal Ideation1
4Not Yet RecruitingPreventionAcute Kidney Injury (AKI)1
4Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
4RecruitingBasic ScienceBipolar Disorder (BD)1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingPreventionMild Cognitive Impairment (MCI)1
4RecruitingTreatmentBipolar Disorder (BD)2
4RecruitingTreatmentBipolar Disorder (BD) / Schizoaffective Disorders1
4RecruitingTreatmentDepressive Disorder, Treatment-Resistant1
4RecruitingTreatmentDepressive Disorders1
4RecruitingTreatmentSarcoma, Osteogenic1
4RecruitingTreatmentThe Use of Antidepressants in Patients With Bipolar Depression1
4TerminatedTreatmentAcute Bipolar Mania1
4TerminatedTreatmentBipolar Disorder (BD)1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusNot AvailableBipolar Affective Disorders1
4Unknown StatusBasic ScienceBipolar Disorder (BD)1
4Unknown StatusTreatmentBipolar I Disorder1
4Unknown StatusTreatmentDepression1
4WithdrawnTreatmentBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)2
Not AvailableCompletedDiagnosticBipolar Disorder (BD) / Mania1
Not AvailableCompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL Negative / Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Disseminated Neuroblastoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Gastrointestinal Complications / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Poor Prognosis Metastatic Gestational Trophoblastic Tumor / Previously Treated Childhood Rhabdomyosarcoma / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Neuroblastoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Small Lymphocytic Lymphoma / Recurrent Wilm's Tumor / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage II Ovarian Epithelial Cancer / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Malignant Testicular Germ Cell Tumor / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Ovarian Epithelial Cancer / Stage III Small Lymphocytic Lymphoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Breast Cancer / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Ovarian Epithelial Cancer / Stage IV Small Lymphocytic Lymphoma1
Not AvailableCompletedTreatmentBipolar Disorder (BD)5
Not AvailableCompletedTreatmentOsteoporosis Pseudoglioma1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingNot AvailableBipolar Disorder (BD) / Bipolar II Depression / Depression / Depression, Bipolar / Major Depressive Episode1
Not AvailableNot Yet RecruitingNot AvailableMild Cognitive Impairment (MCI)1
Not AvailableNot Yet RecruitingTreatmentDepression / Suicidal Ideation/Behavior1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingBasic ScienceAffective Disorders1
Not AvailableRecruitingBasic ScienceBipolar Disorder (BD) / Depression, Bipolar / Unipolar Depression1
Not AvailableRecruitingTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD)1
Not AvailableTerminatedPreventionDepressive Disorders / Suicide1
Not AvailableTerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral300 mg
CapsuleOral600 mg
CapsuleOral150 mg
SolutionOral8 meq/5mL
CapsuleOral150 mg/1
CapsuleOral300 mg/1
CapsuleOral600 mg/1
Capsule, gelatin coatedOral150 mg/1
Capsule, gelatin coatedOral300 mg/1
Capsule, gelatin coatedOral600 mg/1
TabletOral300 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral450 mg/1
Tablet, film coated, extended releaseOral300 mg/1
TabletOral450 mg/1
Tablet, extended releaseOral300 mg
SyrupOral8 mmol
Prices
Unit descriptionCostUnit
Eskalith cr 450 mg tablet0.8USD tablet
Lithium Carbonate 450 mg Controlled Release Tabs0.56USD tab
Lithium Carbonate 300 mg Controlled Release Tabs0.5USD tab
Lithium Carbonate 600 mg capsule0.44USD capsule
Lithium Carbonate 300 mg capsule0.29USD capsule
Lithium Carbonate 300 mg tablet0.29USD tablet
Lithate 20 mg capsule0.28USD capsule
Lithium carb powder reagent0.27USD g
Lithium carbonate 300 mg tab0.22USD each
Lithium Carbonate 150 mg capsule0.21USD capsule
Lithium Citrate 8meq/5ml Syrup0.15USD ml
Lithium citrate 8 meq/5 ml sol0.14USD ml
Pms-Lithium Carbonate 600 mg Capsule0.14USD capsule
Carbolith 150 mg Capsule0.13USD capsule
Lithate 5 mg capsule0.12USD capsule
Lithane 150 mg Capsule0.11USD capsule
Lithane 300 mg Capsule0.11USD capsule
Carbolith 300 mg Capsule0.1USD capsule
Apo-Lithium Carbonate 150 mg Capsule0.06USD capsule
Apo-Lithium Carbonate 300 mg Capsule0.06USD capsule
Pms-Lithium Carbonate 150 mg Capsule0.06USD capsule
Pms-Lithium Carbonate 300 mg Capsule0.06USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180.5International Labour Organization
boiling point (°C)1336International Labour Organization
water solubilityViolent reactionInternational Labour Organization
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9199
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8854
CYP450 2C9 inhibitorNon-inhibitor0.9224
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9487
CYP450 3A4 inhibitorNon-inhibitor0.9853
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.623
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-d37172edddcf6ff27879
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-d37172edddcf6ff27879
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-d37172edddcf6ff27879
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-00619c7d65eb4b7f8f3d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-00619c7d65eb4b7f8f3d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-00619c7d65eb4b7f8f3d

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous alkali metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkali metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous alkali metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous alkali metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous alkali metal
Molecular Framework
Not Available
External Descriptors
alkali metal cation, monovalent inorganic cation, monoatomic monocation (CHEBI:49713) / a cation (LI+)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by pho...
Gene Name
GSK3B
Uniprot ID
P49841
Uniprot Name
Glycogen synthase kinase-3 beta
Molecular Weight
46743.865 Da
References
  1. Borsotto M, Cavarec L, Bouillot M, Romey G, Macciardi F, Delaye A, Nasroune M, Bastucci M, Sambucy JL, Luan JJ, Charpagne A, Jouet V, Leger R, Lazdunski M, Cohen D, Chumakov I: PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar disorder. Pharmacogenomics J. 2007 Apr;7(2):123-32. Epub 2006 May 30. [PubMed:16733521]
  2. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M: Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry. 2007 Dec 1;62(11):1295-302. Epub 2007 Jul 12. [PubMed:17628506]
  3. O'Brien WT, Klein PS: Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009 Oct;37(Pt 5):1133-8. doi: 10.1042/BST0371133. [PubMed:19754466]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain....
Gene Name
IMPA1
Uniprot ID
P29218
Uniprot Name
Inositol monophosphatase 1
Molecular Weight
30188.59 Da
References
  1. Sarkar S, Rubinsztein DC: Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy. 2006 Apr-Jun;2(2):132-4. Epub 2006 Apr 6. [PubMed:16874097]
  2. Trinquet E, Fink M, Bazin H, Grillet F, Maurin F, Bourrier E, Ansanay H, Leroy C, Michaud A, Durroux T, Maurel D, Malhaire F, Goudet C, Pin JP, Naval M, Hernout O, Chretien F, Chapleur Y, Mathis G: D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem. 2006 Nov 1;358(1):126-35. Epub 2006 Aug 30. [PubMed:16965760]
  3. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T: Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem. 2007 Jan 5;282(1):637-46. Epub 2006 Oct 26. [PubMed:17068342]
  4. Tanizawa Y, Kuhara A, Inada H, Kodama E, Mizuno T, Mori I: Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev. 2006 Dec 1;20(23):3296-310. [PubMed:17158747]
  5. Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, Inada T, Kunugi H, Tatsumi M, Ozaki N, Iwata N, Sakamoto K, Iijima Y, Iwata Y, Tsuchiya KJ, Sugihara G, Nanko S, Osumi N, Detera-Wadleigh SD, Kato T, Yoshikawa T: A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology. 2007 Aug;32(8):1727-37. Epub 2007 Jan 24. [PubMed:17251911]
  6. Li Z, Stieglitz KA, Shrout AL, Wei Y, Weis RM, Stec B, Roberts MF: Mobile loop mutations in an archaeal inositol monophosphatase: modulating three-metal ion assisted catalysis and lithium inhibition. Protein Sci. 2010 Feb;19(2):309-18. doi: 10.1002/pro.315. [PubMed:20027624]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Can use myo-inositol monophosphates, scylloinositol 1,4-diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. Has been implicated as the pharmacological target for lith...
Gene Name
IMPA2
Uniprot ID
O14732
Uniprot Name
Inositol monophosphatase 2
Molecular Weight
31320.525 Da
References
  1. Cryns K, Shamir A, Shapiro J, Daneels G, Goris I, Van Craenendonck H, Straetemans R, Belmaker RH, Agam G, Moechars D, Steckler T: Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology. 2007 Apr;32(4):881-91. Epub 2006 Jul 12. [PubMed:16841073]
  2. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T: Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem. 2007 Jan 5;282(1):637-46. Epub 2006 Oct 26. [PubMed:17068342]
  3. Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, Inada T, Kunugi H, Tatsumi M, Ozaki N, Iwata N, Sakamoto K, Iijima Y, Iwata Y, Tsuchiya KJ, Sugihara G, Nanko S, Osumi N, Detera-Wadleigh SD, Kato T, Yoshikawa T: A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology. 2007 Aug;32(8):1727-37. Epub 2007 Jan 24. [PubMed:17251911]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Potentiator
General Function
Extracellular-glutamate-gated ion channel activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA3
Uniprot ID
P42263
Uniprot Name
Glutamate receptor 3
Molecular Weight
101155.975 Da
References
  1. Karkanias NB, Papke RL: Lithium modulates desensitization of the glutamate receptor subtype gluR3 in Xenopus oocytes. Neurosci Lett. 1999 Dec 31;277(3):153-6. [PubMed:10626836]

Drug created on July 06, 2007 13:50 / Updated on November 19, 2017 20:34